PMA device
Cervista Hpv Hr and Genfind Kit
Hologic, Inc. · Kit, Dna Detection, Human Papillomavirus (MAQ, Class III) · First FDA decision Dec 12, 2011, newest Apr 29, 2014Cervical cancer and HPV
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
PMA pathway
Device trials
0
Naming "Cervista Hpv Hr"
MAUDE reports
0
Brand "Cervista Hpv Hr", since 2015
PubMed studies
36
Mentioning "Cervista Hpv Hr"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Cervista Hpv Hr and Genfind Kit
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- CERVISTA HPV HR AND GENFIND KITPMA supplement
P080014-S018 · Decided Apr 29, 2014 · 272 days after receipt · Normal 180 Day Track No User Fee
Device type: KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS (MAQ) · Laboratory Medicine & Pathology
2 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Screening for Cervical Cancer with Human Papillomavirus (HPV) TestingNational analysisReview closedCAG-00442NUpdated Sep 22, 2026
- Screening for Cervical Cancer with Human Papillomavirus (HPV)National determinationOn the books210.2.1Updated Jun 17, 2020
Clinical trials
Device studies on ClinicalTrials.gov that name "Cervista Hpv Hr", any status and sponsor, newest update first.
No registered device study names "Cervista Hpv Hr".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Cervista Hpv Hr", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code MAQ
310 reports: 306 malfunction, 3 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Cervista Hpv Hr"[tiab]. The summary above synthesizes these.
- Cervista HPV HR test for cervical cancer screening: a comparative study in the Catalonian population.
Alameda F, Garrote L, Mojal S, et al. · Arch Pathol Lab Med · 2015Comparative Study
- 2020 list of human papillomavirus assays suitable for primary cervical cancer screening.
Arbyn M, Simon M, Peeters E, et al. · Clin Microbiol Infect · 2021Meta-Analysis, Systematic Review
- Cervista HPV HR test kit in cervical cancer screening.
Wiwanitkit V · J Low Genit Tract Dis · 2013Evaluation Study, Letter
- Comparison of the cervista HPV HR test and luminex XMAP technology for the diagnosis of cervical intraepithelial neoplasia.
Zhao PY, Jiang HC, Li Y, et al. · Eur J Obstet Gynecol Reprod Biol · 2017Clinical Trial, Comparative Study
- Clinical performance characteristics of the Cervista HPV HR test kit in cervical cancer screening in China.
Zhao J, Zhang X, Ma J, et al. · J Low Genit Tract Dis · 2012Evaluation Study, Multicenter Study
- Clinical experience with the Cervista HPV HR assay: correlation of cytology and HPV status from 56,501 specimens.
Youens KE, Hosler GA, Washington PJ, et al. · J Mol Diagn · 2011Comparative Study, Evaluation Study
- Analytical performance of cervista HPV 16/18 in SurePath pap specimens.
Guo M, Khanna A, Feng J, et al. · Diagn Cytopathol · 2015
- Clinical validation of the Cervista HPV HR test according to the international guidelines for human papillomavirus test requirements for cervical cancer screening.
Boers A, Wang R, Slagter-Menkema L, et al. · J Clin Microbiol · 2014Validation Study
- Comparing the Cervista HPV HR test and Hybrid Capture 2 assay in a Dutch screening population: improved specificity of the Cervista HPV HR test by changing the cut-off.
Boers A, Slagter-Menkema L, van Hemel BM, et al. · PLoS One · 2014Comparative Study, Research Support, Non-U.S. Gov't
- Maximizing the adequacy of Hologic(®) Cervista(®) HPV HR results on ThinPrep(®) Pap samples treated with glacial acetic acid.
Mahajan A, Kucher E, Hoefle W, et al. · Diagn Cytopathol · 2016
- Use of Cervista HPV HR assay for detection of human papillomavirus in samples with hybrid capture borderline negative results.
Galan-Sanchez F, Rodriguez-Iglesias MA · APMIS · 2010
- Cervista HPV assays for fine-needle aspiration specimens are a valid option for human papillomavirus testing in patients with oropharyngeal carcinoma.
Guo M, Khanna A, Dhillon J, et al. · Cancer Cytopathol · 2014Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code MAQ.
- cobas HPVRoche Molecular Systems, Inc. · PMA 2026
- BD Onclarity HPV Assay Reagent Pack (SKU 444075) and BD COR HPV Extraction Trough (SKU 444074)Becton, Dickinson and Company · PMA 2026
- Digene Hybrid Capture 2 (HC2) Hpv Dna TestsQiagen Gaithersburg, Inc. · PMA 2015
- Alinity m HR HPVAbbott Molecular, Inc. · PMA 2026
- Cervista Hpv 16/18Hologic, Inc. · PMA 2014
- Onclarity HPV AssayBecton, Dickinson and Company · PMA 2025
- Digene HC2 High Risk Hpv Dna Test and Digene HC2 Hpv Dna TestQiagen Gaithersburg, Inc. · PMA 2014
- Digene Hybrid CAPTURE2Qiagen Gaithersburg, Inc. · PMA 2009
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.